Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET-2 in Recurrent Clostridium Difficile Infection
NCT02865616Phase 1Completed
- Sponsor
- NuBiyota
- Start
- Oct 2017
- Primary completion
- Mar 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MET-2 in Clostridioides difficile infection (CDI), sponsored by NuBiyota. Primary endpoint: Clinical resolution of diarrhea with no CDI relapse at 30 days. Started Oct 2017; status: completed.
02
Drugs
MET-2
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02865616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02865616.